000914703 000__ 03201cam\a2200469Ia\4500
000914703 001__ 914703
000914703 005__ 20230306150406.0
000914703 006__ m\\\\\o\\d\\\\\\\\
000914703 007__ cr\un\nnnunnun
000914703 008__ 190921s2019\\\\sz\\\\\\ob\\\\001\0\eng\d
000914703 019__ $$a1121264960
000914703 020__ $$a9783030244248$$q(electronic book)
000914703 020__ $$a3030244245$$q(electronic book)
000914703 0247_ $$a10.1007/978-3-030-24
000914703 035__ $$aSP(OCoLC)on1120695308
000914703 035__ $$aSP(OCoLC)1120695308$$z(OCoLC)1121264960
000914703 040__ $$aEBLCP$$beng$$cEBLCP$$dGW5XE$$dLQU$$dOCLCF
000914703 049__ $$aISEA
000914703 050_4 $$aRC280.L9
000914703 08204 $$a616.99446$$223
000914703 24500 $$aResistance to targeted therapies in lymphomas /$$cAna C. Xavier, Mitchell S. Cairo, editors.
000914703 260__ $$aCham :$$bSpringer,$$c2019.
000914703 300__ $$a1 online resource (220 pages).
000914703 336__ $$atext$$btxt$$2rdacontent
000914703 337__ $$acomputer$$bc$$2rdamedia
000914703 338__ $$aonline resource$$bcr$$2rdacarrier
000914703 4901_ $$aResistance to targeted anti-cancer therapeutics,$$x2196-551X ;$$vv. 21
000914703 504__ $$aIncludes bibliographical references and index.
000914703 5050_ $$aMechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies -- Resistance to Monoclonal Antibody Therapeutics in Lymphoma -- Resistance to Antibody-Drug Conjugate -- Resistance to Proteasome Inhibitor Therapy in Non-Hodgkin Lymphoma -- Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma -- Resistance to Brutons Tyrosine Kinase Signaling Pathway Targeted Therapies -- Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs -- Resistance to Bispecific T-cell Engagers and Bispecific Antibodies -- Resistance to Chimeric antigen receptor T-cell therapy -- Index.
000914703 506__ $$aAccess limited to authorized users.
000914703 520__ $$aThis volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era.
000914703 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed September 25, 2019).
000914703 650_0 $$aLymphomas$$xTreatment.
000914703 650_0 $$aDrug resistance.
000914703 7001_ $$aXavier, Ana C.
000914703 7001_ $$aCairo, Mitchell S.,$$d1950-
000914703 77608 $$iPrint version:$$aXavier, Ana C.$$tResistance to Targeted Therapies in Lymphomas$$dCham : Springer,c2019$$z9783030244231
000914703 830_0 $$aResistance to targeted anti-cancer therapeutics ;$$vv. 21.
000914703 852__ $$bebk
000914703 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-030-24424-8$$zOnline Access$$91397441.1
000914703 909CO $$ooai:library.usi.edu:914703$$pGLOBAL_SET
000914703 980__ $$aEBOOK
000914703 980__ $$aBIB
000914703 982__ $$aEbook
000914703 983__ $$aOnline
000914703 994__ $$a92$$bISE